Division of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Division of Emergency, The First Affiliated Hispital of Soochow University, Suzhou, China.
Cardiology. 2024;149(2):95-103. doi: 10.1159/000535370. Epub 2023 Nov 22.
Mortality from acute myocardial infarction (AMI) remains substantial. The current study is aimed at developing a novel simple risk score for AMI.
The Coronary Artery Tree description and Lesion EvaluaTion (CatLet) extended validation trial (ChiCTR2000033730) and the CatLet validation trial (ChiCTR-POC-17013536), both being registered with
Of 26 candidate predictor variables, the four strongest predictors for 4-year mortality were included in this novel risk score with an acronym of BACEF (serum alBumin, Age, serum Creatinine, and LVEF). This score was well calibrated and yielded an AUC (95% CI) statistics of 0.84 (0.80-0.87) in internal validation, 0.89 (0.83-0.95) in internal-external (temporal) validation, and 0.83 (0.77-0.89) in external validation. Notably, it outperformed the ACEF, ACEF II, GRACE scores with respect to 4-year mortality prediction.
A simple risk score for 4-year mortality risk stratification was developed, extensively validated, and calibrated in patients with AMI. This novel BACEF score may be a useful risk stratification tool for patients with AMI.
急性心肌梗死(AMI)的死亡率仍然很高。本研究旨在开发一种新的简单 AMI 风险评分。
冠状动脉树描述和病变评估(CatLet)扩展验证试验(ChiCTR2000033730)和 CatLet 验证试验(ChiCTR-POC-17013536),均在
在 26 个候选预测变量中,4 年死亡率的四个最强预测因子包含在这个新的风险评分中,缩写为 BACEF(血清白蛋白、年龄、血清肌酐和 LVEF)。该评分具有良好的校准度,内部验证的 AUC(95%CI)统计数据为 0.84(0.80-0.87),内部-外部(时间)验证为 0.89(0.83-0.95),外部验证为 0.83(0.77-0.89)。值得注意的是,它在预测 4 年死亡率方面优于 ACEF、ACEF II 和 GRACE 评分。
在 AMI 患者中开发了一种用于 4 年死亡率风险分层的简单风险评分,经过广泛验证和校准。这种新的 BACEF 评分可能是 AMI 患者的一种有用的风险分层工具。